For a study, it was determined that inflammatory bowel diseases (IBD) were chronic inflammatory illnesses of the intestine caused by a complicated disruption of the physiologic interaction between the host immune system and intestinal microorganisms triggered by environmental factors. The intestinal microbiome of patients with ulcerative colitis (UC), a kind of IBD, was altered in composition and function in several outcomes. Confounding circumstances, such as concomitant pharmaceutical use, may compromise the precision of these results. To address these constraints, the researchers looked at the microbiome of the colonic mucosa of juvenile UC patients before starting treatment. The researchers discovered a substantial drop in the species Verrucomicrobia in individuals with UC based on bacterial 16S rRNA gene sequencing. The short-chain fatty acid producer Roseburia showed a considerable drop at the genus level. Despite these disparities in composition, the researchers found no differences in inferred gene content between the UC and control groups. The researchers examined the clinical course of UC patients retrospectively to determine if microbial taxa were linked to clinical outcomes. Despite having similar OTU richness and diversity measures, there were major OTU discrepancies between patients who responded to medication and those who did not. The contributions of gut bacteria to illness initiation and modulation were supported by the researchers of the mucosal microbiome and their relationships with diverse clinical outcomes.
Link:www.tandfonline.com/doi/full/10.1080/19490976.2016.1190073
